missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Description
MIA1609 targets Apolipoprotein B in ELISA, IP and RIA applications and shows reactivity with Human samples. The MIA1609 immunogen is purified human serum LDL. MIA1609 detects Apolipoprotein B which has a predicted molecular weight of approximately 502 kDa. MIA1609 was formerly sold as a Seradyn product.
Apolipoprotein B (apo B) in human plasma is a major protein of low density lipoproteins (LDL) with a molecular mass of approximately 260-500 kDa. Apolipoprotein B binds to specific receptors on cell membranes and is involved in removal of LDL and very low density lipoprotein (VLDL) cholesterol from circulation. Low-density lipoprotein (LDL) is the carrier protein for cholesterol in the blood. LDL binds to its receptor on the capillary walls and thereby mediates the uptake and clearance of cholesterol from the circulation. In atherosclerotic lesions oxidatively modified LDL is found and oxidized LDL is specifically recognized and ingested by macrophages via scavenger receptor A and CD36. Oxidized LDL may be a marker of atherosclerosis but the precise changes in oxidized LDL are not well described. MDA-oxidized LDL appear to be different from LDL oxidized by other means. Apolipoprotein B is mostly synthesized in the liver, and is a major apolipoprotein of very low density, intermediate density and low density lipoproteins (LDL) as well as being a major component of lipoprotein (a). Apolipoprotein B is a ligand for the LDL receptor and elevated levels are associated with premature atherosclerosis. Normal plasma apolipoprotein B levels are around 800mg/L. Apolipoprotein B occurs in plasma as two main isoforms, apoB-48 and apoB-100. The intestinal and the hepatic forms of Apolipoprotein B are encoded by a single gene from a single, very long mRNA. The two isoforms share a common N-terminal sequence. The shorter apoB-48 protein is produced after RNA editing of the apoB-100 transcript at residue 2180 (CAA->UAA), resulting in the creation of a stop codon, and early translation termination. Mutations in the Apolipoprotein B gene or its regulatory region cause hypobetalipoproteinemia, normotriglyceridemic hypobetalipoproteinemia, and hypercholesterolemia due to ligand-defective Apolipoprotein B, diseases affecting plasma cholesterol and Apolipoprotein B levels.
Specifications
Specifications
| Antigen | Apolipoprotein B |
| Applications | ELISA, Immunoprecipitation, Radioimmune Assays (RIA), Western Blot, Immunocytochemistry |
| Classification | Monoclonal |
| Clone | F2C9 |
| Concentration | 5 mg/mL |
| Conjugate | Unconjugated |
| Formulation | PBS with 0.09% sodium azide; pH 7.4 |
| Gene | APOB |
| Gene Accession No. | P04114 |
| Gene Alias | Aa1064; Ac1-060; AI315052; Apo B100; Apo B-100; Apo B-48; APOB; apo-B; ApoB 100; ApoB 48; ApoB-100; apob-48; apolipo b; apolipoprotein B; apolipoprotein B (including Ag(x) antigen); Apolipoprotein B 100; Apolipoprotein B 48; apolipoprotein B PI; Apolipoprotein B100; apolipoprotein B-100; apolipoprotein B46; apolipoprotein B47; apolipoprotein B48; Apolipoprotein B-48; apolipoprotein B49; FLDB; LDLCQ4; LOX-1; mCG_129875; MGC176318; Ox-LDL receptor 1 |
| Show More |
Product Title
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.
Spot an opportunity for improvement?